Dacarbazine belongs to the group of medicines called alkylating agents. It is used to treat cancer of the lymph system and malignant melanoma (a type of skin cancer). It may also be used to treat other kinds of cancer, as determined by your doctor. Technically, dacarbazine is a synthetic triazenyl imidazole carboxamide prodrug administered by intravenous infusion, typically dosed by body surface area in mg per square meter, and it is activated hepatically to a methylating species that modifies DNA. Pharmacokinetic properties include rapid hepatic biotransformation, a plasma half life suitable for intermittent dosing schedules, and primary elimination via renal excretion of metabolites. Clinically relevant parameters include requirement for hematologic monitoring because of dose limiting myelosuppression, assessment of liver function prior to and during treatment, and potential interactions mediated by hepatic enzyme activity. Formulation considerations for the active pharmaceutical ingredient include control of moisture, stability in freeze-dried or solution forms, and validated analytical methods such as HPLC for assay and impurity profiling.
Parent: Dacarbazine / Temozolomide
Parent: Dacarbazine
Parent: Dacarbazine
Parent: Dacarbazine
Parent: Temozolomide / Dacarbazine
Typical quality specifications for dacarbazine active pharmaceutical ingredient include an assay range around 98.0 to 102.0 percent by validated HPLC, individual related substances typically limited to 0.2 percent or lower, total related substances limited to 1.0 percent or less, and unspecified impurities controlled at the ICH reporting thresholds (generally 0.1 percent for low dose substances, adjusted per ICH Q3A guidance and based on maximum daily dose). Known related compounds and degradation products to monitor include N-demethylated and desmethyl triazenes, hydrolysis products such as aminated imidazole derivatives (for example 5-aminoimidazole-4-carboxamide type species), structural isomers, and oxidative products; residual solvents and water content must also meet ICH Q3C and Q3 guidelines, with typical residual solvent limits set to Class 2 thresholds and water by Karl Fischer controlled to specification. Analytical control strategies commonly combine HPLC with MS confirmation, dissolution or solubility testing, and stability-indicating forced-degradation studies to characterize impurity formation pathways.
Dacarbazine is used primarily to treat Hodgkin lymphoma and malignant melanoma, and it may be prescribed for other malignancies at the physician’s discretion; it is given intravenously as part of single agent therapy or combination chemotherapy regimens, with treatment selection and scheduling guided by tumor type, stage, and patient performance status.
Dacarbazine is a prodrug that undergoes hepatic biotransformation to generate a methylating intermediate that transfers methyl groups to DNA bases, principally guanine residues, causing miscoding and strand breaks that lead to tumor cell death; this DNA methylation underlies its cytotoxic activity and accounts for schedule dependent effects and resistance mechanisms such as enhanced DNA repair.
Dacarbazine is a chemotherapy agent, specifically an alkylating type prodrug that exerts cytotoxic effects through chemical modification of DNA, not an immunotherapy that directly modulates the immune response.
Disadvantages include dose limiting myelosuppression with risk of neutropenia and thrombocytopenia, significant nausea and vomiting requiring antiemetic prophylaxis, potential hepatotoxicity, flu-like symptoms, variable response rates in solid tumors such as melanoma, and emergence of resistance via DNA repair pathways; careful monitoring and supportive care are required during treatment.
